

July 23, 2013

Steven D. Singleton Limestone Fund, LLC 1600 Division Street, Suite 580 Nashville, TN 37203

Dear Mr. Singleton:

Pursuant to Series B2 Stock Purchase Agreement entered into as of June 7, 2013, by and between Limestone Fund, LLC and Pathfinder Therapeutics, Inc., a Delaware Corporation, Limestone Fund, LLC, has purchased a Series B3 Preferred Stock of Pathfinder Therapeutics, Inc. for \$50,000.

Thank you,

ohany Drake

Pathfinder President